/ORINF

ORINF Stock - Orion Oyj

Q: What is the analyst price target for ORINF?

Analyst price target information is not currently available for ORINF.

Q: What is ORINF's market cap?

Market capitalization information is not currently available for ORINF.

Healthcare|Drug Manufacturers - General|OTC

$81.30+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $89.43

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for ORINF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.30

52W High$81.30

52W Low$48.65

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$1.54B	$1.19B	$1.34B	$1.04B	$1.08B
Gross Profit	$946.40M	$657.70M	$849.00M	$593.50M	$651.10M
Gross Margin	61.4%	55.3%	63.3%	57.0%	60.4%
Operating Income	$416.60M	$274.90M	$439.60M	$243.30M	$280.10M
Net Income	$329.90M	$216.80M	$349.50M	$193.80M	$219.90M
Net Margin	21.4%	18.2%	26.1%	18.6%	20.4%
EPS	$2.34	$1.54	$2.49	$1.38	$1.57

Company Overview

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as consumers with pets. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) product portfolio for the treatment of asthma and COPD; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

Visit Website

Earnings History & Surprises

ORINF

Beat Rate

68%

Last 19 quarters

Avg Surprise

+6.7%

EPS vs Estimate

Beats / Misses

13/5

1 met exactly

Latest EPS

$0.94

Q4 2025

EPS Surprise History

Q1 24

+29.8%

$0.59vs$0.45

Q2 24

-2.5%

$0.34vs$0.34

Q3 24

+12.9%

$0.40vs$0.35

Q4 24

+5.9%

$1.25vs$1.18

Q1 25

+5.7%

$0.54vs$0.51

Q2 25

+12.4%

$0.48vs$0.43

Q3 25

+13.9%

$0.69vs$0.61

Q4 25

+16.5%

$0.94vs$0.81

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Feb 4, 2026	—	—	—	—
Q4 2025	Oct 28, 2025	$0.81	$0.94	+16.5%	✓ BEAT
Q3 2025	Jul 18, 2025	$0.61	$0.69	+13.9%	✓ BEAT
Q2 2025	Apr 23, 2025	$0.43	$0.48	+12.4%	✓ BEAT
Q1 2025	Feb 25, 2025	$0.51	$0.54	+5.7%	✓ BEAT
Q4 2024	Oct 29, 2024	$1.18	$1.25	+5.9%	✓ BEAT
Q3 2024	Aug 8, 2024	$0.35	$0.40	+12.9%	✓ BEAT
Q2 2024	Apr 25, 2024	$0.34	$0.34	-2.5%	✗ MISS
Q1 2024	Mar 20, 2024	$0.45	$0.59	+29.8%	✓ BEAT
Q3 2023	Sep 30, 2023	$0.39	$0.46	+19.8%	✓ BEAT
Q2 2023	Jun 30, 2023	$0.38	$0.28	-24.7%	✗ MISS
Q1 2023	Mar 31, 2023	$0.35	$0.34	-2.3%	✗ MISS
Q1 2023	Feb 9, 2023	$0.28	$0.23	-17.9%	✗ MISS
Q4 2022	Oct 20, 2022	$1.32	$1.38	+4.5%	✓ BEAT
Q3 2022	Jul 15, 2022	$0.35	$0.47	+34.3%	✓ BEAT
Q2 2022	Apr 28, 2022	$0.39	$0.41	+5.1%	✓ BEAT
Q1 2022	Feb 10, 2022	$0.28	$0.23	-17.9%	✗ MISS
Q4 2021	Oct 20, 2021	$0.32	$0.32	0.0%	= MET
Q3 2021	Jul 19, 2021	$0.35	$0.40	+14.3%	✓ BEAT
Q2 2021	Apr 27, 2021	$0.36	$0.42	+16.7%	✓ BEAT

Frequently Asked Questions about ORINF

What is ORINF's current stock price?

Orion Oyj (ORINF) is currently trading at $81.30 per share. The stock has moved +0.00% today.

What is the analyst price target for ORINF?

No analyst price targets are currently available for this stock.

What sector is Orion Oyj in?

Orion Oyj operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. The company is traded on the OTC exchange.

What is ORINF's market cap?

Orion Oyj has a market capitalization of $11.43 billion, making it a large-cap company.

Does ORINF pay dividends?

No, Orion Oyj does not currently pay a dividend to shareholders.